Literature DB >> 21558423

Internal deletion compromises the stability of dystrophin.

Davin M Henderson1, Joseph J Belanto, Bin Li, Hanke Heun-Johnson, James M Ervasti.   

Abstract

Duchenne muscular dystrophy (DMD) is a deadly and common childhood disease caused by mutations that disrupt dystrophin protein expression. Several miniaturized dystrophin/utrophin constructs are utilized for gene therapy, and while these constructs have shown promise in mouse models, the functional integrity of these proteins is not well described. Here, we compare the biophysical properties of full-length dystrophin and utrophin with therapeutically relevant miniaturized constructs using an insect cell expression system. Full-length utrophin, like dystrophin, displayed a highly cooperative melting transition well above 37°C. Utrophin constructs involving N-terminal, C-terminal or internal deletions were remarkably stable, showing cooperative melting transitions identical to full-length utrophin. In contrast, large dystrophin deletions from either the N- or C-terminus exhibited variable stability, as evidenced by melting transitions that differed by 20°C. Most importantly, deletions in the large central rod domain of dystrophin resulted in a loss of cooperative unfolding with increased propensity for aggregation. Our results suggest that the functionality of dystrophin therapeutics based on mini- or micro-constructs may be compromised by the presence of non-native protein junctions that result in protein misfolding, instability and aggregation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21558423      PMCID: PMC3131041          DOI: 10.1093/hmg/ddr199

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  46 in total

1.  Structure of a WW domain containing fragment of dystrophin in complex with beta-dystroglycan.

Authors:  X Huang; F Poy; R Zhang; A Joachimiak; M Sudol; M J Eck
Journal:  Nat Struct Biol       Date:  2000-08

Review 2.  Probing protein structure by limited proteolysis.

Authors:  Angelo Fontana; Patrizia Polverino de Laureto; Barbara Spolaore; Erica Frare; Paola Picotti; Marcello Zambonin
Journal:  Acta Biochim Pol       Date:  2004       Impact factor: 2.149

Review 3.  Function and genetics of dystrophin and dystrophin-related proteins in muscle.

Authors:  Derek J Blake; Andrew Weir; Sarah E Newey; Kay E Davies
Journal:  Physiol Rev       Date:  2002-04       Impact factor: 37.312

4.  Utrophin binds laterally along actin filaments and can couple costameric actin with sarcolemma when overexpressed in dystrophin-deficient muscle.

Authors:  Inna N Rybakova; Jitandrakumar R Patel; Kay E Davies; Peter D Yurchenco; James M Ervasti
Journal:  Mol Biol Cell       Date:  2002-05       Impact factor: 4.138

5.  Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

Authors:  E P Hoffman; R H Brown; L M Kunkel
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

6.  Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene.

Authors:  P M Wakefield; J M Tinsley; M J Wood; R Gilbert; G Karpati; K E Davies
Journal:  Gene Ther       Date:  2000-02       Impact factor: 5.250

7.  Protein interactions leading to conformational changes monitored by limited proteolysis: apo form and fragments of horse cytochrome c.

Authors:  B Spolaore; R Bermejo; M Zambonin; A Fontana
Journal:  Biochemistry       Date:  2001-08-14       Impact factor: 3.162

8.  Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.

Authors:  Scott Q Harper; Michael A Hauser; Christiana DelloRusso; Dongsheng Duan; Robert W Crawford; Stephanie F Phelps; Hollie A Harper; Ann S Robinson; John F Engelhardt; Susan V Brooks; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

9.  Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule.

Authors:  Akanchha Kesari; Laura N Pirra; Lakshmi Bremadesam; Orinthal McIntyre; Erynn Gordon; Alberto L Dubrovsky; V Viswanathan; Eric P Hoffman
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

10.  The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein.

Authors:  M Koenig; A P Monaco; L M Kunkel
Journal:  Cell       Date:  1988-04-22       Impact factor: 41.582

View more
  23 in total

1.  Impacts of dystrophin and utrophin domains on actin structural dynamics: implications for therapeutic design.

Authors:  Ava Yun Lin; Ewa Prochniewicz; Davin M Henderson; Bin Li; James M Ervasti; David D Thomas
Journal:  J Mol Biol       Date:  2012-04-11       Impact factor: 5.469

2.  Disease-proportional proteasomal degradation of missense dystrophins.

Authors:  Dana M Talsness; Joseph J Belanto; James M Ervasti
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-21       Impact factor: 11.205

3.  Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.

Authors:  Karen Anthony; Sebahattin Cirak; Silvia Torelli; Giorgio Tasca; Lucy Feng; Virginia Arechavala-Gomeza; Annarita Armaroli; Michela Guglieri; Chiara S Straathof; Jan J Verschuuren; Annemieke Aartsma-Rus; Paula Helderman-van den Enden; Katherine Bushby; Volker Straub; Caroline Sewry; Alessandra Ferlini; Enzo Ricci; Jennifer E Morgan; Francesco Muntoni
Journal:  Brain       Date:  2011-11-18       Impact factor: 13.501

4.  The carboxy-terminal third of dystrophin enhances actin binding activity.

Authors:  Davin M Henderson; Ava Yun Lin; David D Thomas; James M Ervasti
Journal:  J Mol Biol       Date:  2011-12-28       Impact factor: 5.469

5.  Independent variability of microtubule perturbations associated with dystrophinopathy.

Authors:  Joseph J Belanto; John T Olthoff; Tara L Mader; Christopher M Chamberlain; D'anna M Nelson; Preston M McCourt; Dana M Talsness; Gregg G Gundersen; Dawn A Lowe; James M Ervasti
Journal:  Hum Mol Genet       Date:  2016-11-15       Impact factor: 6.150

6.  Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.

Authors:  Aurélie Goyenvalle; Jordan Wright; Arran Babbs; Vivienne Wilkins; Luis Garcia; Kay E Davies
Journal:  Mol Ther       Date:  2012-02-21       Impact factor: 11.454

7.  Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.

Authors:  Jin-Hong Shin; Xiufang Pan; Chady H Hakim; Hsiao T Yang; Yongping Yue; Keqing Zhang; Ronald L Terjung; Dongsheng Duan
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

8.  Mouse models of two missense mutations in actin-binding domain 1 of dystrophin associated with Duchenne or Becker muscular dystrophy.

Authors:  Jackie L McCourt; Dana M Talsness; Angus Lindsay; Robert W Arpke; Paul D Chatterton; D'anna M Nelson; Christopher M Chamberlain; John T Olthoff; Joseph J Belanto; Preston M McCourt; Michael Kyba; Dawn A Lowe; James M Ervasti
Journal:  Hum Mol Genet       Date:  2018-02-01       Impact factor: 6.150

Review 9.  Large in-frame 5' deletions in DMD associated with mild Duchenne muscular dystrophy: Two case reports and a review of the literature.

Authors:  Elizabeth M Gibbs; Florian Barthélémy; Emilie D Douine; Natalie C Hardiman; Perry B Shieh; Negar Khanlou; Rachelle H Crosbie; Stanley F Nelson; M Carrie Miceli
Journal:  Neuromuscul Disord       Date:  2019-09-24       Impact factor: 4.296

10.  The N-terminal actin-binding tandem calponin-homology (CH) domain of dystrophin is in a closed conformation in solution and when bound to F-actin.

Authors:  Surinder M Singh; Krishna M G Mallela
Journal:  Biophys J       Date:  2012-11-07       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.